Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
Items 201–300 of 1,000
Imaging of anticancer drug action in single cells
Miller, M. A., & Weissleder, R. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.41 · Cited by 92
Regan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92
“Losartan inhibition of TGFb’s fibrogenic effects normalized the extracellular matrix to relieve tumor solid stress, resulting in blood vessel decompression and improved chemotherapeutic efficacy (57, 58).”
BackgroundTruffi, M., Mazzucchelli, S., Bonizzi, A., Sorrentino, L., Allevi, R., Vanna, R., Morasso, C., & Corsi, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061263 · Cited by 94
“Losartan, an angiotensin inhibitor, was assembled with C16-N peptide hydrogels and injected in a murine model of triple negative breast cancer, where it inhibited collagen I synthesis by CAF [46].”
BackgroundMethodGuo, J. X., Zeng, H., & Chen, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00014 · Cited by 100
Pancreatic cancer: The microenvironment needs attention too!
Apte, M. V., Xu, Z., Pothula, S. P., Goldstein, D., Pirola, R. C., & Wilson, J. S. (2015) · Pancreatology · doi:10.1016/j.pan.2015.02.013 · Cited by 104
“Blockade of the angiotensin II receptor using olmasartan, reduced tumour growth in a subcutaneous xenograft model of pancreatic cancer [38], while another angiotensin II receptor blocker, losartan decreased aSMA positivity as well as collagen and hyaluronan production in orthotopic pancreatic tumours [39].”
MethodWu, X., Zhu, Y., Huang, W., Li, J., Zhang, B., Li, Z., & Yang, X. (2018) · Advanced Science · doi:10.1002/advs.201700859 · Cited by 89
Kalli, M., Li, R., Mills, G. B., Stylianopoulos, T., & Zervantonakis, I. K. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0266 · Cited by 95
Self-citationModeling pancreatic cancer in mice for experimental therapeutics
Mallya, K. B., Gautam, S. K., Aithal, A., Batra, S. K., & Jain, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188554 · Cited by 97
Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism
Yang, F., Lee, G., & Fan, Y. (2024) · Angiogenesis · doi:10.1007/s10456-024-09913-z · Cited by 94
“Strategies targeting cancer-associated fibroblasts and the extracellular matrix, such as inhibiting TGF-β [58] or sonic hedgehog pathways [59], and using Nab-paclitaxel [60], show promise in reducing vessel compression.”
MethodMechanical forces in the tumor microenvironment: roles, pathways, and therapeutic approaches
Zhang, Y., Fu, Q., Sun, W., Yue, Q., He, P., Niu, D., & Zhang, M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06306-8 · Cited by 104
“This alleviates solid stress and increases vascular perfusion, improving drug and oxygen delivery in tumors [237].”
Zhang, B., Jiang, T., Shen, S., She, X., Tuo, Y., Hu, Y., Pang, Z., & Jiang, X. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.048 · Cited by 92
“consequently reducing vascular perfusion [13, 14].”
BackgroundThe Paradoxical Web of Pancreatic Cancer Tumor Microenvironment
Lafaro, K. J., & Melstrom, L. G. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.09.009 · Cited by 89
“Similarly, losartan reduced the density of a-SMAepositive cells, decreased collagen and hyaluronan expression, enhanced chemotherapy efficacy, and attenuated hypoxia in orthotopic mouse models.(89) This was thought to be mediated through transforming growth factor-b1, CTGF, and endothelin-1, all of which control PSC p…”
BackgroundNanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix
Kolosnjaj-Tabi, J., Marangon, I., Nicolas-Boluda, A., Silva, A. K. A., & Gazeau, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.010 · Cited by 86
Mechanotransduction at the Plasma Membrane-Cytoskeleton Interface
Uray, I. P., & Uray, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111566 · Cited by 90
“The angiotensin receptor I blocker, losartan, can reduce both collagen I and hyaluronic acid, as well as inhibit TGF-β action [195].”
BackgroundSmall molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective
Zheng, W., Tian, E., Liu, Z., Zhou, C., Yang, P., Tian, K., Liao, W., Li, J., & Ren, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.968104 · Cited by 96
Zhou, T., Xie, Y., Hou, X., Bai, W., Li, X., Liu, Z., Man, Q., Sun, J., Fu, D., Yan, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02671-8 · Cited by 87
Cortés, E., Lachowski, D., Robinson, B. K., Sarper, M., Teppo, J., Thorpe, S. D., Lieberthal, T. J., Iwamoto, K., Lee, D. A., Okada, M., et al. (2018) · EMBO Reports · doi:10.15252/embr.201846557 · Cited by 91
“Angiotensin inhibitors have also been proposed to alleviate solid stress in pancreatic cancer models by reducing collagen and hyaluronan production, resulting in increased blood vessel density, reduced hypoxia along with improved vascular perfusion, and increased delivery of cytotoxic drugs [6].”
Fu, L., Jin, W., Zhang, J., Zhu, L., Lu, J., Zhen, Y., Zhang, L., Ouyang, L., Liu, B., & Yu, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.006 · Cited by 83
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors
Giordano, S., Morosi, L., Veglianese, P., Licandro, S. A., Frapolli, R., Zucchetti, M., Cappelletti, G., Falciola, L., Pifferi, V., Visentin, S., et al. (2016) · Scientific Reports · doi:10.1038/srep37027 · Cited by 92
The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
Hassani, B., Attar, Z., & Firouzabadi, N. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03080-9 · Cited by 88
“Researchers have discovered that the common ARB medicine, losartan, plays a role in lowering tumor growth rates in human pancreatic, breast, and prostate cancer cell xenografts [77, 167, 168].”
BackgroundIslam, W., Niidome, T., & Sawa, T. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12121964 · Cited by 88
Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression
Pothula, S. P., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2020) · Pancreatology · doi:10.1016/j.pan.2020.01.003 · Cited by 86
Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors
Chen, Y., Song, W., shen, L., Qiu, N., Hu, M., Liu, Y., Liu, Q., & Huang, L. (2019) · ACS Nano · doi:10.1021/acsnano.8b07830 · Cited by 77
Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities
Caramelo, B., Zagorac, S., Corral, S., Marqués, M., & Real, F. X. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.02.011 · Cited by 87
Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer
Whatcott, C. J., Ng, S., Barrett, M. T., Hostetter, G., Von Hoff, D. D., & Han, H. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183871 · Cited by 79
Ray, A., & Provenzano, P. P. (2021) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2021.05.004 · Cited by 80
Yu, W., Hu, C., & Gao, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113909 · Cited by 81
Shi, H., Niu, M., Tan, L., Liu, T., Shao, H., Fu, C., Ren, X., Ma, T., Ren, J., Li, L., et al. (2015) · Chemical Science · doi:10.1039/c5sc00781j · Cited by 80
Self-citationCombinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
Seliger, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00999 · Cited by 84
Sun, Z., Wang, X., Liu, J., Wang, Z., Wang, W., Kong, D., & Leng, X. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00937 · Cited by 79
Fu, Y., Ye, F., Zhang, X., He, Y., Li, X., Tang, Y., Wang, J., & Gao, D. (2022) · ACS Nano · doi:10.1021/acsnano.2c06356 · Cited by 79
Integrative models of vascular remodeling during tumor growth
Rieger, H., & Welter, M. (2015) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1295 · Cited by 87
“The simulation results of [89] also demonstrated that increasing the permeability of tumor tissue itself has the potential to improve drug delivery, supporting experimental observations reviewed in [17, 49].”
BackgroundResultSmart Porous Silicon Nanoparticles with Polymeric Coatings for Sequential Combination Therapy
Xu, W., Thapa, R., Liu, D., Nissinen, T., Granroth, S., Närvänen, A. T. O., Suvanto, M., Santos, H. A., & Lehto, V. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00473 · Cited by 79
Nel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 84
Wang, D., Li, Y., Ge, H., Ghadban, T., Reeh, M., & Güngör, C. (2022) · Cancers · doi:10.3390/cancers14163998 · Cited by 85
Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment
Raaijmakers, K., Adema, G. J., Bussink, J., & Ansems, M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03251-0 · Cited by 88
Shen, S., Liu, M., Li, T., Lin, S., & Mo, R. (2017) · Biomaterials Science · doi:10.1039/c7bm00297a · Cited by 81
Targeting extracellular matrix stiffness for cancer therapy
Feng, X., Cao, F., Wu, X., Xie, W., Wang, P., & Jiang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1467602 · Cited by 87
Strategies for improving drug delivery: nanocarriers and microenvironmental priming
Khalid, A., Persano, S., Shen, H., Zhao, Y., Blanco, E., Ferrari, M., & Wolfram, J. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1243527 · Cited by 73
“For instance, anti-TGF-β antibodies [99] and angiotensin inhibitors [94] have been shown to reduce stromal content and improve drug delivery to tumors.”
BackgroundThe peritumor microenvironment: physics and immunity
Zhang, S., Regan, K., Najera, J., Grinstaff, M. W., Datta, M., & Nia, H. T. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.004 · Cited by 83
Kim, B. G., Sung, J. S., Jang, Y., Cha, Y. J., Kang, S., Han, H. H., Lee, J. H., & Cho, N. H. (2019) · Communications Biology · doi:10.1038/s42003-019-0553-9 · Cited by 79
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 79
“Angiotensin receptor blockers (ARBs) normalize the matrix and decompress vessels, reducing the adverse effects of antiangiogenic therapy [170].”
BackgroundRevisiting the role of cancer-associated fibroblasts in tumor microenvironment
Lan, X., Li, W., Zhao, K., Wang, J., Li, S., & Hai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582532 · Cited by 84
Collagen Complexity Spatially Defines Microregions of Total Tissue Pressure in Pancreatic Cancer
Nieskoski, M. D., Marra, K. A., Gunn, J. R., Hoopes, P. J., Doyley, M. M., Hasan, T. G., Trembly, B. S., & Pogue, B. W. (2017) · Scientific Reports · doi:10.1038/s41598-017-10671-w · Cited by 79
Prediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
“Pre-clinical studies have examined multiple strategies for tumor priming, including local radiation therapy [62, 95], cytotoxic chemotherapy [96], extracellular matrix-degrading treatments such as hyaluronidase [18], angiotensin-II receptor inhibitors such as losartan to affect vascular perfusion [19] or production of…”
BackgroundMiroshnikova, Y. A., Rozenberg, G. I., Cassereau, L., Pickup, M., Mouw, J. K., Ou, G., Templeman, K. L., Hannachi, E.-I., Gooch, K. J., Sarang-Sieminski, A. L., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-02-0126 · Cited by 74
“Moreover, reducing cell tension or interstitial pressure or preventing matrix stiffening by inhibiting collagen cross-linking decreases tumor incidence and aggression and can improve treatment efficacy (Paszek et al., 2005; Levental et al., 2009; Samuel et al., 2011; Provenzano et al., 2012; Chauhan et al., 2013; Mill…”
BackgroundKim, D. J., Dunleavey, J. M., Xiao, L., Ollila, D. W., Troester, M. A., Otey, C. A., Li, W., Barker, T. H., & Dudley, A. C. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0072-3 · Cited by 77
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 71
Self-citationThe Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
Wu, Y., Zhang, C., Jiang, K., Werner, J., Bazhin, A. V., & D’Haese, J. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621937 · Cited by 71
“The other inhibitor, losartan, was also shown to decrease the solid pressure in tumor and increase the vascular perfusion by reducing the collagen and HA production in PDAC mouse models (164).”
BackgroundThe Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers
Kozlova, N., Grossman, J. E., Iwanicki, M. P., & Muranen, T. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.01.001 · Cited by 73
Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy
Chen, J., Ding, Z., Li, S., Liu, S., Xiao, C., Li, Z., Zhang, B., Chen, X., & Yang, X. (2020) · Theranostics · doi:10.7150/thno.51383 · Cited by 82
Aoki, S., Inoue, K., Klein, S., Halvorsen, S. C., Chen, J., Matsui, A., Nikmaneshi, M. R., Kitahara, S., Hato, T., Chen, X., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-322493 · Cited by 78
“35 The myofibroblast CAF phenotype may be regulated by several pathways, including Rho GTPase, c-Jun N-terminal kinase and Hedgehog.”
Self-citationDrug delivery: Beyond active tumour targeting
Sagnella, S. M., McCarroll, J. A., & Kavallaris, M. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.04.012 · Cited by 75
“Finally, Chauhan et al showed that administration of the angiotensin inhibitor losartan significantly reduced tumour stromal ECM and hyaluronan production, which in turn decreased the expression of profibrotic signalling and tumour vessel compression.(36) This leads to improved tumour oxygen levels and increased drug…”
BackgroundCai, K., Wang, A. Z., Yin, L., & Cheng, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.034 · Cited by 80
Jena, B. C., Das, C. K., Bharadwaj, D., & Mandal, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188416 · Cited by 80
Yang, H., Tong, Z., Sun, S., & Mao, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.024 · Cited by 68
Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity
Nerini, I. F., Morosi, L., Zucchetti, M., Ballerini, A., Giavazzi, R., & D’Incalci, M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.105 · Cited by 72
Tumor Microenvironment on a Chip: The Progress and Future Perspective
Ahn, J., Sei, Y., Jeon, N., & Kim, Y. (2017) · Bioengineering · doi:10.3390/bioengineering4030064 · Cited by 69
Hydroxyethyl starch-folic acid conjugates stabilized theranostic nanoparticles for cancer therapy
Wang, C., Wang, Q., Wang, H., Li, Z., Chen, J., Zhang, Z., Zeng, H., Yu, X., Yang, X., Yang, X., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.059 · Cited by 73
Obesity and Cancer: An Angiogenic and Inflammatory Link
Fukumura, D., Incio, J., Shankaraiah, R. C., & Jain, R. K. (2016) · Microcirculation · doi:10.1111/micc.12270 · Cited by 69
“For instance, in pancreatic cancer, the limited effectiveness of therapy may be attributed to the fibro-inflammatory microenvironment, which causes vessel compression that limits perfusion and directly hinders drug penetration [2,23,24,37,66,120,124].”
BackgroundSelf-citationLai, Y., Su, C.-Y., Cheng, H., Chu, C., Jeng, L., Chiang, C., Shyu, W., & Chen, S. (2023) · Nature Communications · doi:10.1038/s41467-023-35935-0 · Cited by 72
Jiang, T., Zhang, B., Shen, S., Tuo, Y., Luo, Z., Hu, Y., Pang, Z., & Jiang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b09458 · Cited by 68
Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits
Maneshi, P., Mason, J. E., Dongre, M., & Öhlund, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787485 · Cited by 73
Boucher, Y., Posada, J. M., Subudhi, S., Rosario, S. R., Gu, L., Kumar, A. S., Kumra, H., Mino-Kenudson, M. A., Talele, N. P., Duda, D. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1630 · Cited by 72
Self-citationNia, H. T., Han, L., Soltani, I., Roughley, P. J., Youcef‐Toumi, K., Grodzinsky, A. J., & Christine Ortiz, B. (2015) · ACS Nano · doi:10.1021/nn5062707 · Cited by 69
Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors
Al-Abd, A. M., Aljehani, Z. K., Gazzaz, R. W., Fakhri, S. H., Jabbad, A. H., Alahdal, A. M., & Torchilin, V. P. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.055 · Cited by 69
Therapeutic targeting of cellular stress responses in cancer
Chen, M., & Xie, S. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12890 · Cited by 72
Extravasating Neutrophils Open Vascular Barrier and Improve Liposomes Delivery to Tumors
Naumenko, V. A., Vlasova, K. Y., Garanina, A. S., Melnikov, P. A., Potashnikova, D. M., Vishnevskiy, D. A., Vodopyanov, S. S., Chekhonin, V. P., Abakumov, M. A., & Majouga, A. G. (2019) · ACS Nano · doi:10.1021/acsnano.9b03848 · Cited by 66
Low, L. E., Wu, J., Lee, J., Tey, B. T., Goh, B. H., Gao, J., Li, F., & Ling, D. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.014 · Cited by 67
Zhao, X., Yang, X., Wang, X., Zhao, X., Zhang, Y., Liu, S., Anderson, G. J., Kim, S.-J., Li, Y., & Nie, G. (2021) · ACS Nano · doi:10.1021/acsnano.0c08860 · Cited by 70
Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma
Ray, A., Callaway, M. K., Rodríguez-Merced, N. J., Crampton, A. L., Carlson, M., Emme, K. B., Ensminger, E. A., Kinne, A. A., Schrope, J. H., Rasmussen, H. R., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.150330 · Cited by 69
Yu, S., Wang, S., Wang, X., & Xu, X. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03518-8 · Cited by 79
“…P Chauhan et al. found that chlorosartan reduced TGF-β-induced activation of CAFs, decreased the production of aberrant tumor tissue ECM components such as HA and collagen by CAFs, and improved vascular perfusion, leading to enhanced delivery of 5-fluorouracil and oxygen to tumor tissue [329].”
BackgroundZhu, Y., Wen, L., Shao, S., Tan, Y., Meng, T., Yang, X., Liu, Y., Liu, X., Yuan, H., & Hu, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.023 · Cited by 66
Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 68
“Targeting both collagen and hyaluronan production by both CAFs and macrophages can allow drugs to reach cancer cells (Chauhan et al., 2013).”
Feng, L., Gai, S., He, F., Dai, Y., Zhong, C., Yang, P., & Lin, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.011 · Cited by 64
Domen, A., Quatannens, D., Zanivan, S. R., Deben, C., Audenaerde, J. R. M. V., Smits, E., Wouters, A., Lardon, F., Roeyen, G., Verhoeven, Y., et al. (2021) · Cancers · doi:10.3390/cancers13050987 · Cited by 68
A Validated Multiscale In-Silico Model for Mechano-sensitive Tumour Angiogenesis and Growth
Vavourakis, V., Wijeratne, P. A., Shipley, R. J., Loizidou, M., Stylianopoulos, T., & Hawkes, D. J. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005259 · Cited by 75
Self-citationZhang, S., Grifno, G. N., Passaro, R., Regan, K., Zheng, S., Hadzipasic, M., Banerji, R., O’Connor, L., Chu, V., Kim, S. Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01080-8 · Cited by 67
“Targeting solid stress, when combined with standard-of-care anticancer treatments, prolongs survival in pre-clinical studies 11,14,23–25 and is currently being evaluated in clinical trials 26 , with promising outcomes 27 .”
BackgroundMethodEvolution of osmotic pressure in solid tumors
Voutouri, C., & Stylianopoulos, T. (2014) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2014.09.019 · Cited by 68
“…stromal cells, collagen and hyaluronic acid contribute to the generation of solid stresses, while solid stress alleviation by selective depletion of any of these components decompresses tumor blood vessels and improves perfusion and drug delivery (Chauhan et al., 2013; Stylianopoulos et al., 2012).”
BackgroundSelf-citationEvaluating the benefits of renin-angiotensin system inhibitors as cancer treatments
Perini, M. V., Dmello, R. S., Nero, T. L., & Chand, A. L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107527 · Cited by 66
Improving nanotherapy delivery and action through image-guided systems pharmacology
Ng, T. S. C., Garlin, M. A., Weissleder, R., & Miller, M. A. (2020) · Theranostics · doi:10.7150/thno.37215 · Cited by 60
“Decreased collagen due to losartan treatment can be assessed by SHG imaging [166, 167], which correlated with improved tumor perfusion and PEGylated liposomal doxorubicin (Doxil) uptake [167] (Figure 7D).”
BackgroundFerruzzi, J., Sun, M., Gkousioudi, A., Pilvar, A., Roblyer, D. M., Zhang, Y., & Zaman, M. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-50268-z · Cited by 64
Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy
Mpekris, F., Voutouri, C., Panagi, M., Baish, J. W., Jain, R. K., & Stylianopoulos, T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.008 · Cited by 62
Self-citationCancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis
Fernández‐Nogueira, P., Fuster, G., Gutiérrez-Uzquiza, Á., Gascón, P., Carbó, N., & Bragado, P. (2021) · Cancers · doi:10.3390/cancers13133146 · Cited by 64
Li, C., Maishi, N., Annan, D. A., Young, M. F., Morimoto, H., Morimoto, M., Nam, J.-M., Hida, Y., & Hida, K. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01423-w · Cited by 65
“Normalization of the tumor microenvironment has also been theorized to enhance drug delivery and the efficiency of chemotherapies [36].”
BackgroundCancer-Associated Fibroblasts: Implications for Cancer Therapy
Maia, A. R. R., & Wiemann, S. (2021) · Cancers · doi:10.3390/cancers13143526 · Cited by 64
Bhargav, A. G., Domino, J. S., Chamoun, R. B., & Thomas, S. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.805628 · Cited by 67
Novel Immunotherapies for Osteosarcoma
Lu, Y., Zhang, J., Chen, Y., Kang, Y., Liao, Z., He, Y., & Zhang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830546 · Cited by 66
Angarola, B. L., Sharma, S. M., Katiyar, N., Kang, H. G., Nehar-Belaid, D., Park, S., Gott, R., Eryilmaz, G. N., LaBarge, M. A., Palucka, K., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00751-8 · Cited by 73
Vessel calibre—a potential MRI biomarker of tumour response in clinical trials
Emblem, K. E., Farrar, C. T., Gerstner, E. R., Batchelor, T. T., Borra, R. J. H., Rosen, B. R., Sorensen, A. G., & Jain, R. K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.126 · Cited by 59
Self-citationKumar, V., Boucher, Y., Liu, H., Ferreira, D., Hooker, J., Catana, C., Hoover, A. J., Ritter, T., Jain, R. K., & Guimaraes, A. R. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.07.004 · Cited by 57
“Address all Radiology, S Sciences Un Portland, O RadiationO E-mail: guim 1Funding:A Y. B. andR R01-CA098 Received 2 © 2016 Th accessarticle 1936-5233 http://dx.d correspondence to: Alexander R. Guimaraes, MD, PhD, Associate Professor o ectionChief, Body Imaging,Department ofDiagnostic Radiology,OregonHealth iversity,…”
InfluentialSelf-citationLi, C., Zheng, X., Chen, W., Ji, S., Yuan, Y., & Jiang, X. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c02272 · Cited by 58
Cancer-Associated Fibroblasts in the Breast Tumor Microenvironment
Giorello, M. B., Borzone, F. R., Labovsky, V., Piccioni, F., & Chasseing, N. A. (2021) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-020-09475-y · Cited by 60
The role of matrix stiffness in cancer stromal cell fate and targeting therapeutic strategies
Wei, J., Yao, J., Yan, M., Xie, Y., Liu, P., Mao, Y., & Li, X. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.08.005 · Cited by 55
Datta, M., Chatterjee, S., Perez, E. M., Gritsch, S., Roberge, S., Duquette, M. A., Chen, I. X., Naxerova, K., Kumar, A. S., Ghosh, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219199120 · Cited by 60
“We have shown that losartan (and similar ARBs) can improve response to cytotoxic and ICB in pancreatic and metastatic breast cancer mouse models, respectively (10, 11).”
BackgroundSelf-citationWang, Z., Kerketta, R., Chuang, Y.-L., Dogra, P., Butner, J. D., Brocato, T. A., Day, A., Xu, R., Shen, H., Simbawa, E. A., et al. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004969 · Cited by 61
Camblin, A. J., Pace, E. A., Adams, S., Curley, M. D., Rimkunas, V. M., Nie, L., Tan, G., Bloom, T., Iadevaia, S., Baum, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2262 · Cited by 58
El‐Magd, M. A., Mohamed, Y., El‐Shetry, E. S., Elsayed, S. A. M., Gazia, M. A., Abdel‐Aleem, G. A., Shafik, N. M., Abdo, W. S., El-Desouki, N. I., & Basyony, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108732 · Cited by 58
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
Bordeau, B. M., & Balthasar, J. P. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0704 · Cited by 58
The extracellular matrix in cancer: from understanding to targeting
Chitty, J. L., & Cox, T. R. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.05.003 · Cited by 71
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.